证券代码：300012 证券简称：华测检测 公告编号：2024-055 华测检测认证集团股份有限公司 公司于 2023 年 12 月 12 日召开第六届董事会第十一次会议审议通过《关于 为子公司开具履约保函的议案》，为全资子公司华测工程检测有限公司（以下简 称"华测工程"）广州市轨道交通十号线工程质量检测服务项目及广州市轨道交 通工程三号线东延段工程质量检测服务项目向银行申请履约保函。上述保函将于 2024 年 12 月 31 日到期。目前项目尚未实施完毕，华测工程与广州地铁集团有 限公司签署了《广州市轨道交通十号线工程质量检测服务项目合同（三）补充协 议》及《广州市轨道交通工程三号线东延段工程质量检测服务项目合同（三）补 充协议》，增加了服务内容，合同金额相应增加。为缓解华测工程保函保证金占 用资金的情况，提高流动资金的使用效率，公司拟继续为华测工程向银行申请开 具保函，本次履约保函金额合计为 1,141,981.06 元，期限为银行开立之日起至 2025 年 12 月 31 日止。华测工程 2024 年 10 月 31 日的资产负债率为 53.26%，无 需提交股东大会审议。 二、被担保人基本情况 1、公 ...

证券代码：300012 证券简称：华测检测 公告编号：2024-053 华测检测认证集团股份有限公司 第六届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 修改后的《战略与ESG委员会工作细则》详见巨潮资讯网（www.cninfo.com.cn）。 一、会议以 7 票同意、0 票反对、0 票弃权，审议通过《关于为子公司开具履 约保函的议案》 董事会认为，公司本次为华测工程检测有限公司开具履约保函是为了满足其 签订项目合同的需要，华测工程检测有限公司是公司全资子公司，公司为其开具 履约保函的风险可控，不会损害公司的整体利益。具体内容详见公司同日于巨潮 资讯网（www.cninfo.com.cn）披露的《关于为子公司开具履约保函的公告》（公 告编号：2024-055）。 二、会议以 4 票同意、0 票反对、0 票弃权，审议通过《关于修改子公司增资 扩股方案的议案》 董事会认为，本次对华测医药增资扩股方案进行修改，仅涉及对华测医药员 工持股计划和华测检测管理层持股平台的"股权流转机制"的修改，符合公司实 际情况，不会影响公司的日常运营和财 ...

华测检测认证集团股份有限公司 董事会战略与 ESG 委员会工作细则 第一章 总则 第一条 为适应公司战略发展需要，健全公司投资决策程序，提高重大投资决策 的效益和决策的质量，完善公司治理结构，根据《中华人民共和国公司法》、《上 市公司治理准则》、《公司章程》及其他有关规定，华测检测认证集团股份有限公 司（"公司"或"本公司"）进一步规范战略与 ESG 委员会（以下简称"委员会"） 的工作流程，制定本实施细则。 第二条 委员会是董事会辖下的专门委员会，对董事会负责，主要负责： 第二章 组成 第三条 战略委员会成员由三至五名董事组成，其中包括至少半数或以上的外部 董事。委员会委员由董事会任命。 第四条 委员会设主任委员（召集人）一名，负责主持委员会工作；主任委员由 董事会任命。 第五条 委员会委员的任期约为三年，任期起止时间应与当届董事任期的起止时 间一致。委员会委员任期届满，可以连选或连任。如有委员于任期内不再担任本 公司董事职务，则自动失去委员资格，并由董事会根据上述第三至第四条规定补 足委员人数。 第六条 委员会下设工作小组，由公司高级管理人员、投资部、董事会办公室及 相关部门负责人组成。工作小组为委员会的 ...

关于修改子公司增资扩股方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300012 证券简称：华测检测 公告编号：2024-056 华测检测认证集团股份有限公司 华测检测认证集团股份有限公司（以下简称"公司"）于2024年11月25日召 开第六届董事会第十九次会议审议通过了《关于修改子公司增资扩股方案的议 案》，现将有关事项公告如下： 一、概述 公司于 2021 年 12 月 29 日召开 2021 年第二次临时股东大会审议通过了《关 于子公司实施增资扩股暨关联交易的议案》，同意子公司上海华测品创医学检测 有限公司（以下简称"华测医药"）以 4.50 元/注册资本的价格（即投前估值 143,795.70 万元）增资扩股。华测医药员工持股计划、华测检测管理层持股平台 及董事长万峰先生实缴金额合计为 24,618.00 万元。本次增资完成后，华测医药 注册资本由 31,954.60 万元增至 37,425.26 万元，华测检测持有华测医药的股权比 例由 100%变更为 85.38%。具体内容详见巨潮资讯网披露的《关于子公司实施增 资扩股暨关联 ...

证券代码：300012 证券简称：华测检测 公告编号：2024-054 一、会议以 3 票同意、0 票反对、0 票弃权，审议通过《关于为子公司开具履 约保函的议案》 监事会认为，公司本次为全资子公司开具履约保函是为了满足子公司履行项 目义务的需要，担保风险可控，不存在损害公司及全体股东利益的情形。具体内 容详见公司同日于巨潮资讯网（www.cninfo.com.cn）披露的《关于为子公司开具 履约保函的公告》（公告编号：2024-055）。 特此公告。 第六届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华测检测认证集团股份有限公司（以下简称"公司"）第六届监事会第十四 次会议于 2024 年 11 月 23 日发出会议通知，2024 年 11 月 25 日以现场结合通讯方 式召开。本次会议应参加监事 3 人，实际参加监事 3 人，分别为：陈炜明、杜学 志、张渝民。本次会议召开符合《公司法》和《公司章程》的有关规定。会议由 公司监事会主席陈炜明先生主持，经与会监事认真审议，形成如下决议： 华测检测认证集团股份有限公司 监 事 会 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][4]. Core Insights - The company reported a revenue of 4.396 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 7.71%. The net profit attributable to shareholders was 747 million yuan, up 0.79% year-on-year [3][4]. - The company has shown steady revenue growth in Q3, with total revenue of 1.605 billion yuan, reflecting a year-on-year growth rate of 5.21% [3]. - The gross margin improved by 0.50 percentage points to 50.88% for the first three quarters of 2024, with Q3 gross margin reaching 53.24%, an increase of 1.16 percentage points year-on-year [3]. - The company is investing in strategic areas such as semiconductor chips and new energy, with plans to invest 280 million yuan in a comprehensive testing service base in Bao'an [3][4]. - The company is also pursuing external growth through acquisitions, including the acquisition of Naias and Hefei Zhongxin Health Management, enhancing its strategic layout in green energy and health management services [3]. Financial Summary - The company is projected to achieve revenues of 6.103 billion yuan, 6.812 billion yuan, and 7.517 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 8.90%, 11.61%, and 10.35% [4][5]. - The net profit attributable to shareholders is expected to be 980 million yuan, 1.118 billion yuan, and 1.254 billion yuan for the same years, with growth rates of 7.71%, 13.99%, and 12.23% [4][5]. - The company's price-to-earnings (P/E) ratios for 2024, 2025, and 2026 are projected to be 24.22, 21.25, and 18.93, respectively [4][5].

华测检测认证集团股份有限公司 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300012 证券简称：华测检测 公告编号：2024-052 （2）中国证监会规定的其他情形。 2、公司以集中竞价交易方式回购股份符合下列要求： （1）委托价格不得为公司股票当日交易涨幅限制的价格； 华测检测认证集团股份有限公司（以下简称"公司"）于 2024 年 7 月 2 日 召开第六届董事会第十六次会议审议通过了《关于回购公司股份方案的议案》， 公司计划使用自有资金以集中竞价方式回购公司股份，回购的公司股份用于员工 持股计划或股权激励。本次拟回购股份数量为 200 万股-300 万股，回购股份价格 不超过人民币 16.83 元/股，按照回购数量上限 300 万股和回购价格上限 16.83 元/ 股的条件下测算，预计回购金额不超过 5,049 万元，具体回购股份的数量以回购 结束时实际回购的股份数量为准。本次回购实施期限为自公司董事会审议通过本 次回购股份方案之日起不超过 12 个月。具体内容详见公司 2024 年 7 月 3 日、2024 年 ...

Investment Rating - The report maintains a "Hold" rating for the company [1] Core Views - The company's performance in Q1-Q3 2024 met expectations, with revenue of 4.4 billion yuan, a year-on-year increase of 7.7%, and a net profit attributable to shareholders of 750 million yuan, up 0.8% year-on-year [1] - The company continues to enhance its operational efficiency through lean management, resulting in a stable increase in gross margin, which reached 50.9% for Q1-Q3 2024, up 0.5 percentage points year-on-year [1] - The traditional testing sector remains robust, with significant growth in various segments, including life sciences, industrial testing, and consumer goods testing [1] - The company is actively expanding into emerging testing fields through strategic acquisitions, enhancing its business layout and demonstrating strong resilience in growth [1] Summary by Sections Financial Performance - For Q3 2024, the company achieved revenue of 1.6 billion yuan, a year-on-year increase of 5.2% and a quarter-on-quarter increase of 0.4% [1] - The net profit for Q3 2024 was 310 million yuan, down 0.8% year-on-year but up 2.0% quarter-on-quarter [1] - The comprehensive gross margin for Q1-Q3 2024 was 50.9%, while the net profit margin was 17.1%, reflecting a slight decrease due to increased R&D and financial expenses [1] Business Segments - The life sciences segment is expanding with projects in environmental testing and food safety, while the industrial testing segment is seeing a successful transformation with improved margins [1] - The company is also focusing on enhancing its capabilities in medical and pharmaceutical services, with rapid growth in laboratory expansions [1] Future Outlook - The company forecasts net profits of 980 million yuan, 1.1 billion yuan, and 1.25 billion yuan for 2024, 2025, and 2026 respectively, with a compound annual growth rate of 11% [1][2] - The current stock price corresponds to a price-to-earnings ratio of 24, 21, and 19 for the next three years [1]

Financial Performance - In the first three quarters of 2024, the company achieved revenue of CNY 4.396 billion, a year-on-year increase of 7.71% [1] - The net profit attributable to shareholders was CNY 747 million, up 0.79% year-on-year; the net profit excluding non-recurring items was CNY 701 million, an increase of 3.18% [1] - The overall gross margin for the first three quarters was 50.88%, an increase of 0.5 percentage points year-on-year [1] - In Q3 2024, revenue was CNY 1.605 billion, a year-on-year decrease of 0.82%, but an increase of 5.21% compared to the previous quarter [1] - The net profit attributable to shareholders in Q3 was CNY 310 million, with a net profit excluding non-recurring items of CNY 298 million, reflecting a year-on-year increase of 1.14% [1] Business Segments Performance - The life sciences segment saw rapid growth in traditional environmental services, benefiting from the smooth progress of the Sanpu project [2] - The environmental monitoring segment continued to enhance monitoring capabilities and expand new pollutant monitoring services, achieving steady growth [2] - The food testing segment maintained operational efficiency and competitive advantages, with rapid growth in cosmetics and daily chemical products [2] - The industrial testing segment performed well in industrial materials, digitalization, and construction, with notable improvements in gross margins [2] - The medical and health services segment showed a positive growth trend in Q3, with high single-digit growth in revenue [2] Strategic Initiatives - The company maintains a cautious yet proactive approach to mergers and acquisitions, successfully acquiring Taiwan Guangyi and Hefei Zhongxin to enhance its service offerings [3] - The company is focusing on high-quality development through lean management, team collaboration, and automation to improve operational efficiency [3] - The management has outlined a "123 strategy" for future growth, focusing on maintaining traditional business stability, investing in new projects, and exploring new fields and technologies [3] Market Outlook - The company anticipates a gradual economic recovery, which is expected to benefit the TIC industry, with stable development projected for Q4 2024 and 2025 [3] - The company is actively monitoring government economic stimulus measures, which are expected to positively impact its core business [5] - The semiconductor industry is viewed positively for long-term growth, despite current challenges [6] Operational Efficiency - The company is implementing various measures to optimize internal processes, reduce waste, and enhance overall operational efficiency [4] - Initiatives include lean management practices, talent development programs, and collaborative efforts across different business units [4] Investor Relations - The company has consistently increased cash dividends and is committed to enhancing shareholder returns through solid performance and governance [8]

Investment Rating - The investment rating for the company is "Outperform the Market" [1][7][9] Core Insights - The company reported a revenue of 4.396 billion yuan for Q1-Q3 2024, representing a year-on-year increase of 7.71%. The net profit attributable to the parent company was 747 million yuan, up 0.79% year-on-year [4][5] - The gross margin for Q1-Q3 2024 was 50.88%, with a net margin of 17.11%. In Q3 2024, the gross margin was 53.24%, reflecting a year-on-year increase of 1.16 percentage points [5] - The company has made strategic acquisitions to enhance its business layout, including the acquisition of a laboratory in Greece to strengthen its global shipping green energy technology service strategy [6][9] Financial Performance Summary - For Q1-Q3 2024, the company achieved a single-quarter revenue of 1.605 billion yuan, a year-on-year increase of 5.21%, while the net profit for the same period was 310 million yuan, down 0.82% year-on-year [4] - The company’s operating cash flow for Q1-Q3 2024 was 274 million yuan, a decrease of 32.41% year-on-year [6] - The company expects to achieve revenues of 6.124 billion yuan, 6.592 billion yuan, and 7.067 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 9.3%, 7.6%, and 7.2% [7][9] Business Segmentation - The company’s revenue from the Life Sciences segment is projected to grow by 15.00%, 8.00%, and 6.00% for 2024, 2025, and 2026, respectively, with a gross margin of 50.00%, 49.00%, and 48.00% [9][10] - The Industrial Testing segment is expected to see revenue growth of 12.00%, 10.00%, and 10.00% over the same period, maintaining a gross margin of 43.00% [9] - The Consumer Testing segment is forecasted to grow by 3.00%, 5.00%, and 8.00% for the next three years, with a gross margin of 43.00% in 2024 [9][11] - The Trade Assurance segment is anticipated to grow by 5.00% annually, maintaining a high gross margin of 67.00% [9][11] - The Pharmaceutical and Medical Services segment is expected to decline by 15.00% in 2024 but recover with growth of 10.00% in the following years, with a gross margin of 24.00% in 2024 [10][11]